Published on:April 2022

Indian Journal of Pharmacy Practice, 2022; 15(2):97-104

Original Article | doi:10.5530/ijopp.15.2.18


Arshamol Varghese1, Tany Maritta George1, Therese Mathew1, Shaji George2,*

1Nirmala College of Pharmacy, Muvattupuzha, Kerala, INDIA.

2Department of Pharmacy Practice, Nirmala College of Pharmacy, Muvattupuzha, Kerala, INDIA.


Background: Heart failure is a disabling condition affecting 26 million people worldwide. Progress in understanding of the pathogenesis of HF has led to new treatments, which include If channel inhibitor ivabradine, which acts selectively and specifically by inhibiting the cardiac pacemaker current If. The purpose of the study is to evaluate the safety and efficacy of ivabradine in HF patients. Materials and Methods: It was a retrospective, observational single-center study done in the Kottayam district of Kerala with a sample size of 391 patients with Chronic Heart Failure, and the data was collected from 2016-2020 using a structured data collection form. Various statistical tests were conducted using SPSS-version 16. Results: Among 391 patients with chronic heart failure 65.22% were males and the remaining were females. A significant reduction in heart rate was observed in patients taking Ivabradine compared to patients not taking Ivabradine. It also reduced the number of hospitalizations among patients. ADR was reported in 27 patients. A greater proportion of patients (188 patients) has been administered with Ivabradine 5mg BD. 128 patients were given 2.5mg BD,49 patients were prescribed with 5mg TID and only 26 patients were given 5 mg OD tablets. Conclusion: Ivabradine is the only agent shown to clinically lower the heart rate without negative inotropism on conduction and contractility. Increased heart rate produces an adverse impact on the myocardium. Ivabradine is an attractive, effective, and safe choice in patients with heart failure.

Key words: Heart failure, Heart rate, Ivabradine, Standard therapy, Treatment outcome, Efficacy